Recurrent Ovarian Germ Cell Tumor Completed Phase 2 Trials for Ondansetron (DB00904)

IndicationStatusPhase
DBCOND0029793 (Recurrent Ovarian Germ Cell Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00795769Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantSupportive Care